BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist DOI Creative Commons

Guillaume Gourdin,

Laure Chotel,

Christelle De La Fouchardière

et al.

Advances in Therapy, Journal Year: 2023, Volume and Issue: 40(8), P. 3281 - 3290

Published: June 14, 2023

This article has been co-authored by a patient with right-sided BRAFV600E metastatic colorectal cancer (mCRC), his caregiver, and an oncologist. Here the caregiver discuss their personal experiences struggling cancer, including fears, expectations, attitudes as disease progresses. The oncologist describes how patients mCRC are treated management strategy can be balanced to mitigate any side effects. Improved diagnostic techniques availability of numerous treatment options, various chemotherapy schemes molecular-targeted drugs, aid rapid implementation algorithms. pivotal roles patients' associations in general support those close them, facilitating link healthcare professionals, highlighted this perspective piece.This French since December 2020, oncologist, physician currently based at Institut Paoli-Calmettes Marseille. Metastatic is characterized high number genetic mutations, each being associated different prognosis response treatment. Around 8–12% will present BRAF mutation tumour, majority which V600E, leading poor standard short overall survival. fears receiving immunotherapy fifth line treatment, while actively communicates patients’ understand more about identify new possibilities. lines received did not follow usual algorithms proposed France for BRAFV600E-mutated cancer. sought clinical trial patient’s third-line from information provided associations. Thus, play key role professionals.

Language: Английский

Biomarkers and theranostics in colorectal cancer DOI
Vidya Sabale,

Shraddha Dubey,

Ashwini Ingole

et al.

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 329 - 385

Published: Jan. 1, 2024

Language: Английский

Citations

0

Biomarkers as a Therapeutic Approach in Colorectal Carcinoma DOI Creative Commons

Rustam Effendi-Ys,

Amido Rey,

Imelda Rey

et al.

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 14, 2024

This review highlights the most promising biomarker tests of tumor tissue from colonoscopy biopsy for more individualized therapeutic approaches to patients with colorectal carcinoma (CRC). Biomarkers are a key tool in early detection, survival, and predicting treatment response prognostic value. The can help doctors select specific CRC targeted therapy. is third common cancer diagnosed, second leading cause cancer-related deaths worldwide, despite progress made detection management through surgery, chemotherapy, radiotherapy, immunotherapy. With population totaling 273,523,621 people, Indonesia has estimated 396,914 new cases all 234,511 deaths. Among those cases, 34,189 17,786 occurred 2020. Most were located rectum compared distal colon or proximal colon. heterogeneous cancer. Its vary, depending on location (proximal, colon, rectum), clinical signs symptoms, staging biomarkers such as KRAS NRAS, BRAF V600E, MSI high (dMMR), CIN, HER2-amplified, PD-1, CTLA-4, MEK, NTRK gene fusion-positive. CSCs other being developed remain under investigation.

Language: Английский

Citations

0

Predictive role of [18F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients DOI Creative Commons

Magdi A. Ali,

Omar Shebl Zahra,

Mohamed Morsi

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 8(1)

Published: Dec. 25, 2024

Abstract Objectives The objective of this study was to evaluate the predictive value 18 F-fluorodeoxyglucose [ F]FDG positron emission tomography (PET-CT) radiomic parameters in relation KRAS/BRAF/EGFR mutations patients with metastatic colorectal cancer (mCRC). Methods Blood samples were collected from 90 mCRC assess KRAS G13V, BRAF V600E, and EGFR exon 20 mutations. PET-CT scans performed, parameters, including SUV max, max TBR, total MTV, TLG, calculated correlated different genotypes haplotypes aforementioned Results TBR significantly greater G13V V600E than wild-type genotype. SUVmax also Haplotype analysis revealed that other patients, a specificity 68.18% sensitivity 65.28%. Conclusion results suggest F] FDG particularly have potential serve as noninvasive tools for predicting mutation status patients.

Language: Английский

Citations

0

Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer DOI Open Access
Chien‐Yu Lin, Ming‐Yin Shen, William Tzu‐Liang Chen

et al.

Journal of Personalized Medicine, Journal Year: 2023, Volume and Issue: 13(7), P. 1051 - 1051

Published: June 26, 2023

KRAS mutation in tumor tissue is a well-known predictor of resistance to the treatment anti-EGFR antibodies metastatic colorectal cancers (mCRC). However, prognostic value low-frequency plasma circulating DNA (ctDNA) predicting pretreated mCRC patients remains controversial. This study retrospectively reviewed clinical course, including response and anti-VEGF therapies, changes serum marker levels along with image studies <1.5% mutations detected ctDNA by next-generation sequencing (NGS) at single center Taiwan. We identified six G12V/G12D/G12S/G13D (variant allele frequency 0.26~1.23%) ctDNA. Co-occurring APC, TP53, MAP2K1, KEAP1, or CTNNB1 were also detected. Although all had adjustments within one month after genetic test, image-evident progression was noted median 4 months afterwards. Re-challenge therapy combination anti-EGFR, anti-VEGF, FOLFIRI chemotherapy found be ineffective patient 0.38% G12D baseline Our suggests that detection could used as patients.

Language: Английский

Citations

1

BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist DOI Creative Commons

Guillaume Gourdin,

Laure Chotel,

Christelle De La Fouchardière

et al.

Advances in Therapy, Journal Year: 2023, Volume and Issue: 40(8), P. 3281 - 3290

Published: June 14, 2023

This article has been co-authored by a patient with right-sided BRAFV600E metastatic colorectal cancer (mCRC), his caregiver, and an oncologist. Here the caregiver discuss their personal experiences struggling cancer, including fears, expectations, attitudes as disease progresses. The oncologist describes how patients mCRC are treated management strategy can be balanced to mitigate any side effects. Improved diagnostic techniques availability of numerous treatment options, various chemotherapy schemes molecular-targeted drugs, aid rapid implementation algorithms. pivotal roles patients' associations in general support those close them, facilitating link healthcare professionals, highlighted this perspective piece.This French since December 2020, oncologist, physician currently based at Institut Paoli-Calmettes Marseille. Metastatic is characterized high number genetic mutations, each being associated different prognosis response treatment. Around 8–12% will present BRAF mutation tumour, majority which V600E, leading poor standard short overall survival. fears receiving immunotherapy fifth line treatment, while actively communicates patients’ understand more about identify new possibilities. lines received did not follow usual algorithms proposed France for BRAFV600E-mutated cancer. sought clinical trial patient’s third-line from information provided associations. Thus, play key role professionals.

Language: Английский

Citations

0